Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring

Citation for published version:

Digital Object Identifier (DOI):
10.1172/JCI1567

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Journal of Clinical Investigation

Publisher Rights Statement:
© 1998, The American Society for Clinical Investigation

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Glucocorticoid Exposure in Late Gestation Permanently Programs Rat Hepatic Phosphoenolpyruvate Carboxykinase and Glucocorticoid Receptor Expression and Causes Glucose Intolerance in Adult Offspring

Moffat J. Nyirenda, Robert S. Lindsay, Chris J. Kenyon, Ann Burchell,* and Jonathan R. Seckl
Molecular Endocrinology Laboratory, Molecular Medicine Centre, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, United Kingdom; and *Department of Obstetrics and Gynaecology, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, United Kingdom

Abstract

Low birth weight in humans is predictive of insulin resistance and diabetes in adult life. The molecular mechanisms underlying this link are unknown but fetal exposure to excess glucocorticoids has been implicated. The fetus is normally protected from the higher maternal levels of glucocorticoids by fetal-placental 11β-hydroxysteroid dehydrogenase type-2 (11β-HSD2) which inactivates glucocorticoids. We have shown previously that inhibiting 11β-HSD2 throughout pregnancy in rats reduces birth weight and causes hyperglycemia in the adult offspring. We now show that dexamethasone (a poor substrate for 11β-HSD2) administered to pregnant rats selectively in the last week of pregnancy reduces birth weight by 10% (P < 0.05), and produces adult fasting hyperglycemia (treated 6.1 ± 0.4; control 3.8 ± 0.5 mmol/l, P = 0.04), reactive hyperglycemia (treated 8.7 ± 0.4; control 7.5 ± 0.2 mmol/l, P = 0.03), and hyperinsulinemia (treated 6.1 ± 0.4; control 3.8 ± 0.5 ng/ml, P = 0.01) on oral glucose loading. In the adult offspring of rats exposed to dexamethasone in late pregnancy, hepatic expression of glucocorticoid receptor (GR) mRNA and phosphoenolpyruvate carboxykinase (PEPCK) mRNA and activity are increased by 25% (P = 0.01) and 60% (P < 0.01), respectively, while other liver enzymes (glucose-6-phosphatase, glucokinase, and 11β-hydroxysteroid dehydrogenase type-1) are unaltered. In contrast dexamethasone, when given in the first or second week of gestation, has no effect on offspring insulin/glucose responses or hepatic PEPCK and GR expression. The increased hepatic GR expression may be crucial, since rats exposed to dexamethasone in utero showed potentiated glucose responses to exogenous corticosterone. These observations suggest that excessive glucocorticoid exposure late in pregnancy predisposes the offspring to glucose intolerance in adulthood. Programmed hepatic PEPCK overexpression, perhaps mediated by increased GR, may promote this process by increasing gluconeogenesis. (J. Clin. Invest. 1998. 101:2174–2181.) Key words: glucocorticoids • 11β-hydroxysteroid dehydrogenase • birth weight • gluconeogenesis • non–insulin-dependent diabetes mellitus

Introduction

Increasing epidemiological evidence in humans suggests a key role for early life events in the development of cardiovascular and metabolic disorders (1, 2). In particular, low birth weight is strongly predictive of hypertension (3), glucose intolerance (4), non-insulin-dependent diabetes mellitus (NIDDM) (5), and death from ischemic heart disease (1, 2) in adult life. The association between birth weight and adult disease is independent of the classical life-style risk factors such as adult weight, social class, smoking, alcohol, and lack of exercise (1). Furthermore, these data reflect a continuous relationship representing birth weights within the normal range, not just severely undersized babies (1). These findings have led to the fetal origins hypothesis which suggests that environmental factors contributing to the pathogenesis of cardiovascular and metabolic diseases act, in part, in utero (6); thus, an adverse intrauterine environment would program or imprint the development of fetal tissues and organs, permanently determining responses, producing later dysfunction and disease. The individual organ system affected is determined by its unique vulnerability, based on the timing of the exposure and the systems developing during that time window (7).

The mechanisms linking intrauterine growth retardation and later disease are poorly defined. Recently, we provided evidence that excessive exposure of the fetus to maternal glucocorticoids might explain the link between low birth weight and subsequent glucose intolerance (8) and hypertension (9). Glucocorticoids have well characterized effects on blood pressure and glucose metabolism in the adult (10), and administration during pregnancy is known to reduce birth weight in humans and animals (11). Moreover, fetal cortisol levels are elevated in human intrauterine growth retardation (12). Steroid hormones are also involved in the development and maturation of various fetal and postnatal organ systems (13, 14), and administration in the perinatal period has been shown to produce permanent programming effects. Neonatal androgen administration, for example, permanently influences hepatic...

1. Abbreviations used in this paper: 11β-HSD2, 11β-hydroxysteroid dehydrogenase type 2; DEX WK, dexamethasone-treated in week of gestation; GR, glucocorticoid receptor; IGF, insulin-like growth factor; IGFBP-1, insulin-like growth factor binding protein-1; NIDDM, non–insulin-dependent diabetes mellitus; PEPCK, phosphoenolpyruvate carboxykinase; pv/pp, perivenous-to-periportal ratio.
metabolic pathways and sexual behavior (15, 16), while perinatal glucocorticoids permanently affect the hypothalamic-pituitary-adrenal axis response to stress (17, 18). Glucocorticoids, which act via nuclear glucocorticoid receptors (GR) to regulate target gene transcription, might act in several ways in a developing animal to provoke later abnormalities in glucose metabolism. Several important hepatic processes, including many enzymes controlling the production and fate of metabolic fuels, are regulated by glucocorticoids. Phosphoenolpyruvate carboxykinase (PEPCK), a key enzyme in gluconeogenesis and an important target gene in NIDDM, is under potent glucocorticoid regulation (19).

The fetus is normally protected from the substantially (5 to 10 times) higher maternal levels of glucocorticoids by placental 11β-hydroxy steroid dehydrogenase type-2 (11β-HSD2). This enzyme catalyzes the rapid conversion of physiologically active glucocorticoids (cortisol in humans, corticosterone in rats) to inert 11-keto products (cortisone and 11-dehydrocorticosterone, respectively) (20, 21). The activity of 11β-HSD2 in the placenta correlates with birth weight (22). Recently, we have shown that administration of carbinoxolone (a potent inhibitor of 11β-HSD2) to rats throughout gestation reduces birth weight and predisposes the offspring to hyperglycemia later in life (7). To test that this effect of carbinoxolone was produced by exposing the fetus to raised levels of glucocorticoids rather than less specific effects on other enzymes (such as 11β-HSD1), a reductase enzyme which amplifies glucocorticoid action by regenerating active 11-hydroxy forms from inert 11-keto steroids, we used dexamethasone, a synthetic glucocorticoid and an important target gene in NIDDM, is under potent glucocorticoid regulation (19).

**Methods**

**Animals.** Female Wistar rats (200–250 g; Harlan UK Ltd., Bicester, UK) were maintained under conditions of controlled lighting (lights on 7:00 a.m. to 7:00 p.m.) and temperature (22°C) and allowed free access to food (standard rat chow; 56.3% carbohydrate, 18.3% protein, 0.7% NaCl; Bruce Smith and Smart Scotland Ltd. Edinburgh) and tap water. The rats were time-mated and divided into four treatment groups (five females per group). Dexamethasone (100 µg/kg per d, dissolved in 4% ethanol–0.9% saline, 200 µg/ml) was given subcutaneously at the first (dexamethasone-treated in week of gestation [DEX WK] 1), DEX WK2, or DEX WK3, with vehicle injections in other weeks; a control group received an injection of vehicle, 0.7% NaCl; Bruce Smith and Smart Scotland Ltd. Edinburgh) to examine whether exposure to exogenous corticosterone on blood glucose concentration, four pellets of corticosterone acetate (250 µg/d corticosterone) were given subcutaneously under halothane anesthesia (controls were sham operated). Fasting blood glucose was measured 3 d after pellets were inserted. After a week, animals were fasted overnight and, after decapitation, their livers removed for GR binding studies and mRNA expression.

**GR binding studies.** Cytosol was prepared from fragments of excised livers for dexamethasone and corticosterone binding studies, as described previously (24). Briefly each liver sample was homogenized in 10 mM Tris-HCl buffer (pH 7.4) containing 2 mM DTT, 1.5 mM EDTA, 0.1 M sodium molybdate, and 10% glycerol. After centrifugation (4°C) at 20,000 and 10,000 g for 20 and 60 min, respectively, the protein content was adjusted to 4 mg/ml. Aliquots (50 µl) of liver cytosol were incubated for 16 h at 4°C in buffer with 1.5 nM [3H]dexamethasone (Amersham International) and various concentrations of either nonradioactive dexamethasone or corticosterone (0.316 nM–100 µM). Free and bound radioactivity were separated with dextrancoated charcoal (5 g/liter charcoal and 1 g/liter dextran T70 in buffer) and bound radioactivity was counted in a liquid scintillation spectrometer (Wallac, Crownhill, UK). Binding constants for dexamethasone and corticosterone were calculated from homologous and heterologous competition curves.

**Enzyme activity.** Fed animals were killed by decapitation between 9:00 and 10:00 a.m. and livers were removed immediately. 10% (wt/vol) fresh liver homogenates were prepared at 0°C in medium containing 250 mM sucrose and 5 mM Hepes (pH 7.4). Homogenates were centrifuged at 3,600 g for 10 min to sediment intact cells. The supernatant fractions were further centrifuged at 130,000 g for 30 min. The resulting supernatant (cytosol) was collected and stored at −70°C for PEPCK and glucokinase assay. Protein content of the preparations was determined by the Peterson method (25). PEPCK activity was assayed at 30°C by coupling the formation of oxalacetate with NADH oxidation in the presence of excess malate dehydrogenase (Boehringer Mannheim UK, Lewes, UK), as described by Petrescu et al. (26). The reaction mixture (1 ml final volume) contained 50 mM Hepes (pH 6.5), 50 mM sodium bicarbonate, 1 mM MgCl₂, 0.25 mM NADH, 1 mM phosphoenolpyruvate, 1.5 U malate dehydrogenase, and 100 µl of liver cytosolic preparation. The reaction was initiated with 0.15 mM deoxy-GDP and the decrease in absorbance at 340 nm was followed for 5 min. A reaction mixture lacking bicarbonate was used as control. Glucokinase was assayed using a continuous spectrometric method adopted from Davidson and Arion (27). The assay medium contained 50 mM sodium Hepes, 100 mM KCl, 7.5 mM MgCl₂, 5 mM ATP, 2.5 mM DTT, 100 mM glucose, 0.5 mM NAD⁺, and 1 U of glucose-6-phosphate dehydrogenase (Sigma Chemical Co.). The activity of 0.01 ml of cytosolic preparation was assayed in a final volume of 1 ml. The reaction was initiated by addition of ATP and the rate of NAD⁺ reduction was recorded at 340 nm. Control medium lacked ATP. Glucose-6-phosphatase activity (in intact and disrupted microsomes) was assayed kinetically as described previously (28).

**RNA probes.** All restriction enzymes and RNA polymers were obtained from Promega UK Ltd. (Southampton, UK). A 360-bp fragment derived from the coding region of rat PEPCK cDNA was generated by PCR using two primers (5′ AGCTGCTATAATG-GTCTGG 3′ and 5′ GAAACCTGGCCGTTAAGTC 3′), and cloned into the pGEM-T easy vector (Promega UK Ltd.). Fidelity of amplifi-
The complementary antisense RNA strand was generated by SP6 RNA polymerase after NcoI linearization of the vector. 

Results

The effect of prenatal dexamethasone on offspring birth weight. Dexamethasone treatment did not affect maternal glucose levels, and there were no differences in length of gestation, litter size, or viability among the groups (data not shown). However, dexamethasone administration in the third week of pregnancy reduced offspring birth weight (treated 5.6±0.1 g; control 6.2±0.1 g, P = 0.004). Treatment during the first or second week of gestation had no significant effects on birth weight (Table I). Body weights of all 3 dexamethasone-treated and control groups were similar at time of weaning (day 21 after birth) and at 6 mo (Table I).

Table I. Effect of Dexamethasone on Offspring Body Weights

<table>
<thead>
<tr>
<th>Group</th>
<th>Birth weight</th>
<th>Weight at day 21</th>
<th>Weight at 6 mo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>6.2±0.1</td>
<td>47.3±3.3</td>
<td>455.6±22.4</td>
</tr>
<tr>
<td>DEX WK1</td>
<td>6.5±0.1</td>
<td>49.7±0.9</td>
<td>454.7±27.3</td>
</tr>
<tr>
<td>DEX WK2</td>
<td>6.1±0.1</td>
<td>50.4±1.0</td>
<td>458.5±18.2</td>
</tr>
<tr>
<td>DEX WK3</td>
<td>5.6±0.1</td>
<td>48.3±1.3</td>
<td>445.8±17.8</td>
</tr>
</tbody>
</table>

Body weights (grams) of the offspring of pregnant rats treated with vehicle alone (Control), DEX WK1, DEX WK2, or DEX WK3 were measured at birth, day 21, and 6 mo. *P < 0.01 compared with control.

Figure 1. Plasma glucose and insulin responses to an oral glucose load in offspring. Offspring of pregnant rats that received vehicle alone (CONTROL, n = 9), DEX WK1 (n = 8), DEX WK2 (n = 13), or DEX WK3 (n = 8) underwent an oral glucose tolerance test at 6 mo. Plasma glucose (A) was measured at 0, 30, and 120 min and insulin (B) was measured at 0 and 30 min after oral glucose load. *P < 0.05 compared to control.
oral glucose load, DEX WK3 offspring had significantly higher 30-min plasma glucose concentrations compared to control (8.7±0.4 vs. 7.5±0.2 mmol/liter, \( P = 0.03 \)). There were no significant differences at 120 min (Fig. 1A). Fasting plasma insulin levels were similar in all the groups, but DEX WK3 offspring had higher 30-min insulin levels after glucose loading than controls (6.1±0.4 vs. 3.8±0.5 ng/ml, \( P = 0.01 \)) (Fig. 1B). DEX WK3 Offspring also showed an elevated 30-min insulin-to-glucose ratio compared to controls (0.71±0.06 vs. 0.50±0.07 \( \mu \)g/mmol, \( P = 0.03 \)), suggesting more insulin secretion per unit of glucose. Dexamethasone administration during either the first or second week of gestation did not significantly affect glucose or insulin levels in the adult offspring.

The effect of prenatal dexamethasone treatment on mRNA expression and activity of hepatic enzymes. Enzyme expression and activity was determined in livers of fed rats. Within the hepatic acinus, PEPCK mRNA expression was higher in the periportal zone than in the perivenous zone in all the groups. This zonation was age-dependent, with the perivenous-to-periportal (pv/pp) ratio increasing from 1:1.5 at birth and peaking to 1:3 by weaning. Dexamethasone administration during the first or second week of gestation significantly reduced periportal PEPCK mRNA expression in the offspring from birth up to 21 d; at 8 mo expression was similar to control (Fig. 2). In contrast, treatment during the third week of pregnancy had no effect on PEPCK expression at birth but permanently increased periportal PEPCK expression from day 5 after birth onwards (Fig. 2). Perivenous PEPCK mRNA expression was not significantly affected by prenatal dexamethasone (data not shown). PEPCK enzyme activities were correspondingly increased in DEX WK3 offspring compared to controls (Fig. 3). Neither glucose-6-phosphatase nor glucokinase activity was affected by dexamethasone treatment (data not shown).

The effect of prenatal dexamethasone on hepatic GR expression. GR mRNA was widely expressed in the liver, with highest levels in the periportal region (pv/pp of 1:1.4). DEX WK3 offspring significantly elevated hepatic GR mRNA expression. (Fig. 4.). The increase in GR was maintained to adult life, but was more marked at day 5 after birth (70%) than at 8 mo (25%). The binding affinity of GR was unaltered by prenatal dexamethasone treatment (Table II).

The effect of prenatal dexamethasone on expression of hepatic 11\( \beta \)-HSD1. 11\( \beta \)-HSD1 was highly expressed in the liver. The distribution of 11\( \beta \)-HSD1 mRNA within the acini was similar to that of GR mRNA, with a pv/pp ratio of 1:1.3. Prenatal dexamethasone administration did not affect levels of expression or distribution of 11\( \beta \)-HSD1 (Fig. 4.).

The effect of exogenous corticosterone on hepatic GR expression. As hepatic GR mRNA was increased in animals that had dexamethasone late in pregnancy, we examined whether this was functionally important by measuring basal (8:30 a.m.) plasma corticosterone levels and by examining whether exogenous corticosterone modulated GR mRNA expression. There were no significant differences in basal plasma corticosterone levels between offspring of dams that had dexamethasone during the third week of pregnancy and controls (DEX WK3, 3.2±0.4; Control, 2.5±0.6 \( P = 0.4 \)). Exogenous corticosterone pellets did not affect the dissociation constant of hepatic GR (Table II), but significantly reduced expression of hepatic GR mRNA in DEX WK3 offspring (Fig. 5). The decrease in GR mRNA expression in controls did not reach statistical sig-
Significance. Even after exogenous corticosterone, GR mRNA expression in animals exposed to dexamethasone in utero remained higher than similarly treated controls (Fig. 5). Exogenous corticosterone significantly increased fasting plasma glucose levels in DEX WK3 offspring while levels in controls were unchanged (Fig. 6).

Discussion

We have shown that dexamethasone administration in the pregnant rat, selectively in the last week of gestation, reduces birth weight and produces fasting and postglucose hyperglycemia and hyperinsulinemia in the adult offspring. These findings are in accord with our earlier observations in which the physiological barrier to glucocorticoids, 11\(\beta\)-HSD2, was inhibited by carbenoxolone throughout pregnancy (8), and directly demonstrate that prenatal exposure to elevated glucocorticoid levels programs glucose metabolism, leading to permanent hyperglycemia and apparent insulin resistance. The effect on both birth weight and glucose–insulin homeostasis of the offspring is significant.

Table II. Hepatic GR Binding Affinity

<table>
<thead>
<tr>
<th>Group</th>
<th>Kd Dex</th>
<th>Kd B</th>
<th>B max (nmol/g protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control+ Sham</td>
<td>4.5±0.4</td>
<td>10.6±1.6</td>
<td>0.29±0.05</td>
</tr>
<tr>
<td>Control+ Cort</td>
<td>5.3±0.4</td>
<td>10.1±2.6</td>
<td>0.24±0.03</td>
</tr>
<tr>
<td>DEX WK3+ Sham</td>
<td>4.4±0.8</td>
<td>8.6±1.3</td>
<td>0.37±0.07</td>
</tr>
<tr>
<td>DEX WK3+ Cort</td>
<td>5.1±0.7</td>
<td>11.5±2.2</td>
<td>0.26±0.04</td>
</tr>
</tbody>
</table>

Adult DEX WK3 offspring were given subcutaneous corticosterone pellets (DEX WK3+ Cort, n = 6) or sham operated (DEX WK3+ Sham, n = 6). Similarly, offspring of vehicle-treated dams received corticosterone pellets (Control+ Cort, n = 6) or sham operation (Control+ Sham, n = 6). 1 wk after operation, GR binding affinity for ligand was determined on liver cytosols of fasted rats. Binding constants for dexamethasone (Dex) and corticosterone (B) were calculated from homologous and heterogenous competition curves.
spring only occurred when dexamethasone was administered during the third week of gestation and not earlier in pregnancy, suggesting a late gestational window of sensitivity to glucocorticoids. The nature of the late period of sensitivity to glucocorticoids is uncertain; GR are expressed in many tissues, including liver, from midgestation onwards (32). Perhaps the congruence of rapid growth in late gestation with the expression of key glucocorticoid-regulated growth factors, such as the insulin-like growth factor (IGF) system, may be of importance. Indeed hepatic production of IGF binding protein-1 (IGFBP-1), which neutralizes the actions of IGF-1, is markedly induced in late gestation fetuses by high-dose maternal dexamethasone treatment (33), and has been advocated as causal in the growth retardation observed. Furthermore, transgenic mice overexpressing IGFBP-1 have low birth weight and adult hyperglycemia (34), perhaps suggesting one mechanism through which glucocorticoids link low birth weight and abnormal glucose metabolism. However, these programming mechanisms are likely to be complex because GR mediates its effects by interacting with several factors. For example, regulation of IGFBP-1 by glucocorticoids involves interaction of GR with hepatic nuclear factor-1 (35), which has been causally linked to diabetes (36). Whatever the mechanisms, the effects of late prenatal glucocorticoids mimic, and might therefore underlie, the human epidemiological associations between low birth weight and later glucose intolerance/NIDDM.

The basis of NIDDM is incompletely understood, but increased hepatic glucose production may be a major contributing factor (37). In adult life, glucocorticoids affect glucose-insulin homeostasis at several levels, by inducing peripheral insulin resistance (38), inhibiting insulin secretion (39), and stimulating gluconeogenesis (37). In early life, glucocorticoids exert important maturational effects on enzymes involved in glucose metabolism, most notably PEPCK (13, 14, 40). Our results show that treatment with dexamethasone during the third week of pregnancy induces permanent overexpression of PEPCK in the offspring, with no effect on glucose-6-phosphatase (another gluconeogenic enzyme) or glucokinase (a glycolytic enzyme), though the decline in the latter approached significance. The effects on PEPCK were transcriptional, in accord with the predominant level of control of this gene product, and were specifically confined to periporal regions, the major sites of gluconeogenesis in the hepatic acinus. Selective increases in gluconeogenic enzyme activity have been documented in various animal models of NIDDM (41, 42). Since PEPCK is the rate limiting enzyme of gluconeogenesis (43), and overexpression of PEPCK in a rat hepatoma cell line impairs suppression of gluconeogenesis (44), it is plausible that increased PEPCK in vivo potentiates hepatic glucose production, producing the observed glucose intolerance. Indeed, transgenic mice overexpressing PEPCK have impaired glucose tolerance (45).

The mechanism by which PEPCK expression is increased by exposure to dexamethasone in utero is unclear. In the adult rat liver, PEPCK gene transcription is increased by glucocorticoids, glucagon (through cAMP), thyroid hormone and retinoic acid, and is negatively and dominantly regulated by insulin (46, 47). The PEPCK gene promoter has two distinct cis elements which are bound by activated GR (48). PEPCK appears in liver with the first lactational feed on the day of birth (49), and is associated with the increase in glucagon-to-insulin ratio (50) and/or the rise in glucocorticoids (40) that occurs at this time. Indeed PEPCK can be induced prematurely by injection of glucagon (51, 52), cAMP (49), and glucocorticoids, at least in the chick (53) and sheep (40). However, in this study dexamethasone in the last week of pregnancy did not alter PEPCK expression at birth, but only from day 5, suggesting an indirect effect. The actions of glucocorticoids in the liver are modulated by 11β-HSD1 which amplifies intracellular glucocorticoid action by catalyzing the conversion of the ample supply of inert circulating metabolites (cortisone and 11-dehydrocorticosterone) into bioactive glucocorticoids (cortisol and corticosterone) (54). Indeed, mice with targeted disruption of the 11β-HSD1 gene show deficient induction of gluconeogenic enzymes (55). However, 11β-HSD1 expression was unaltered by prenatal dexamethasone, and was not enriched peripartally, providing no support for this idea.

In contrast, prenatal dexamethasone permanently increased GR expression in the liver. The increase in hepatic GR mRNA expression occurred in the presence of maintained (i.e., unpressed) glucocorticoids and unaltered GR binding affinity for ligand. This is an intriguing finding, since GR mRNA levels are often negatively autoregulated by circulating glucocorticoids (56). Indeed exogenous corticosterone administration achieved some downregulation of GR mRNA in these animals. However, hepatic GR levels in animals exposed to dexamethasone in utero remained higher than similarly treated controls. This finding suggests that glucocorticoids are able to downregulate GR in offspring of dexamethasone-treated dams, but that the basal set point of hepatic GR expression is higher compared to controls. Several, possibly species-specific, molecular mechanisms of regulation of GR expression have been suggested. In the mouse GR expression is controlled by at least three promoters, one of which is preferentially used in T lymphocytes (57). Rat mRNA also shows high variability at the 5′ end, suggesting expression from different transcriptional start sites and/or promoters (58). The rise in hepatic GR mRNA expression in offspring that were exposed to dexamethasone in utero, may well reflect induction of a liver-specific promoter, since GR mRNA is decreased by the same treatment in hippocampal neurons (18). Increased hepatic GR expression, in the presence of maintained corticosterone levels and unaltered GR binding affinity, suggests that prenatal dexamethasone may program enhanced glucocorticoid mediated responses, such as induction of hepatic PEPCK expression. This contention is supported by the increased blood glucose sensitivity which these rats show to exogenous glucocorticoids. The lack of effect on other glucocorticoid-sensitive mRNAs and enzymes may well reflect the complex control of these gene products.

Fetal nutrition is also important in determining prenatal growth and maternal lack of nutrition is associated with later disease, including hypertension and diabetes (2). Specifically, maternal protein restriction during rat pregnancy produces offspring showing hypertension and hyperglycemia, with altered hepatic enzyme profiles including increased PEPCK activity (59). It is possible that the effects of glucocorticoids and lack of nutrition have a common underlying mechanism. Indeed maternal protein restriction during rat pregnancy attenuates placental 11β-HSD2 activity (60), suggesting that excessive glucocorticoid exposure may mediate, in part, the effects of a lack of nutrition. Moreover, hypertension induced by a maternal low-protein diet in the rat is prevented by inhibitors of glucocorticoid synthesis (61). Thus, fetal overexposure to...
glucocorticoids may represent a common link between the maternal environment, fetal growth, and later cardiovascular and metabolic diseases, notably NIDDM.

Acknowledgments

We thank Val Lyons, Susan Nelson, and Pamela Houston for their excellent technical assistance, and Drs. Dieter Schmoll, Günther Schütz, Carl Monder, Perrin White, and Roger Miesfeld for cDNA cloning.

These studies were supported by a Wellcome Senior Clinical Research Fellowship (Jonathan R. Seckl) and a Program Grant from the Wellcome Trust. Mffat J. Nyirenda is the recipient of an Overseas Research Studentship and a World Health Organization fellowship.

References


